Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

In patients with neuroendocrine tumours (NETs), a combination of morphological imaging
and nuclear medicine techniques is mandatory for primary tumour visualization, staging and …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

The diagnosis of neuroendocrine tumours (NETs) and monitoring of therapy in many
patients relies mainly on morphological imaging techniques such as computed tomography …

Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …

A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …

Purpose Somatostatin receptors (SSTR) are known for an overexpression in
gastroenteropancreatic neuroendocrine tumours (GEP-NET). The aim of the present study …

Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We
herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled …